Becton, Dickinson and Company (BDX) Shares Sold by Forbes J M & Co. LLP

Forbes J M & Co. LLP decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,763 shares of the medical instruments supplier’s stock after selling 265 shares during the quarter. Forbes J M & Co. LLP’s holdings in Becton, Dickinson and were worth $929,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Almanack Investment Partners LLC. purchased a new stake in shares of Becton, Dickinson and during the 1st quarter worth approximately $105,000. Parkside Financial Bank & Trust boosted its stake in shares of Becton, Dickinson and by 1.4% during the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after acquiring an additional 9 shares in the last quarter. QCI Asset Management Inc. NY boosted its stake in shares of Becton, Dickinson and by 9.2% during the 1st quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after acquiring an additional 60 shares in the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in shares of Becton, Dickinson and by 55.8% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after acquiring an additional 240 shares in the last quarter. Finally, Financial Architects Inc boosted its stake in shares of Becton, Dickinson and by 8.0% during the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after acquiring an additional 54 shares in the last quarter. 87.12% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company (NYSE BDX) opened at 197.51 on Thursday. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63. The firm has a 50-day moving average price of $197.04 and a 200 day moving average price of $192.83. The firm has a market capitalization of $44.95 billion, a P/E ratio of 57.20 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same quarter last year, the business posted $2.35 EPS. The company’s revenue was down 5.1% on a year-over-year basis. Equities research analysts anticipate that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 29th. Investors of record on Friday, September 8th were paid a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a yield of 1.48%. The ex-dividend date was Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is 83.43%.

Several equities research analysts have recently commented on BDX shares. Raymond James Financial, Inc. raised Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price target for the stock from $210.00 to $180.00 in a research note on Friday, June 30th. Cowen and Company reissued an “outperform” rating and set a $230.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. BidaskClub raised Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target on the stock in a research note on Monday, July 17th. Finally, Bank of America Corporation reissued a “buy” rating and set a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $200.93.

In related news, insider Ellen R. Strahlman sold 9,283 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the transaction, the insider now owns 26,638 shares of the company’s stock, valued at approximately $5,279,917.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the transaction, the insider now directly owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock valued at $15,242,688 in the last ninety days. Company insiders own 1.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Becton, Dickinson and Company (BDX) Shares Sold by Forbes J M & Co. LLP” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/10/12/becton-dickinson-and-company-bdx-shares-sold-by-forbes-j-m-co-llp.html.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply